Meeting
2019 ASCO Annual Meeting
Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.
Authors
Marcelo Vailati Negrao
Department of Thoracic / Head and Neck Medical Oncology - The University of Texas MD Anderson Cancer Center, Houston, TX
Marcelo Vailati Negrao , Victoria M. Raymond , Richard B. Lanman , Patrick Kwok Shing Ng , Rebecca Nagy , Kimberly Banks , Viola Weijia Zhu , Bianca E Amador , Emily Roarty , Young Kwang Chae , Jeffrey Melson Clarke , Jeffrey Crawford , Sai-Hong Ignatius Ou , David R. Gandara , John Heymach , Trever Grant Bivona , Caroline Elizabeth McCoach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3102)
DOI
10.1200/JCO.2019.37.15_suppl.3102
Abstract #
3102
Poster Bd #
94
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
First Author: Zeynep Eroglu
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.
First Author: Yuki Matsubara